Oncolytic Virus Cancer Therapy - Pipeline Insight, 2022

January 2022 | 140 pages | ID: OBEFEDF16AB6EN
DelveInsight

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight’s, “Oncolytic Virus Cancer Therapy - Pipeline Insight, 2022” report provides comprehensive insights about 45+ companies and 85+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Oncolytic Virus Cancer Therapy Understanding

Oncolytic Virus Cancer Therapy: Overview

Oncolytic virus (OV) cancer therapies are the virus based therapeutic strategies that infect and destroy cancer cells, and therefore act as an in situ cancer vaccine by releasing tumor-specific antigens. Viruses such as myxoma virus or reovirus have inherent selectivity to tumor cells, while being nonpathogenic to healthy human cells. On the other hand, other OVs, including adenovirus, herpes simplex virus type-1 (HSV-1), and vesicular stomatitis virus (VSV), have been genetically engineered to function as vectors to boost anti-tumor immune responses. The therapeutic efficacy of Oncolytic viruses depends on two main modes of action: First, Oncolytic viruses can inhibit protein synthesis of tumor cells and destroy infected tumor cells by self-replication. After viral infection, Oncolytic viruses continue self-replication until the cell bursts; Second, Oncolytic viruses can recruit and activate tumor-infiltrating immune cells by releasing a large amount of tumor antigens and secreting cytokines. Oncolytic virus cancer therapies can be used for diagnosis as well treatment of cancer. The anti-tumor efficacies of these OVs have been evaluated in many preclinical and clinical studies as monotherapy and combination therapy.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Oncolytic Virus Cancer Therapy R&D. The therapies under development are focused on novel approaches for Oncolytic Virus Cancer Therapy.

Oncolytic Virus Cancer Therapy Emerging Drugs Chapters

This segment of the Oncolytic Virus Cancer Therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Oncolytic Virus Cancer Therapy Emerging Drugs

• CG0070: CG Oncolgy

CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070, first replicates inside the tumor’s cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body’s own white blood cells. CG0070 is in development for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators. The therapy is in clinical development for the treatment of Bladder cancer and preclinical studies for solid tumors. In advanced clinical studies, CG0070 has been shown to be a safe and efficacious agent in NMIBC following BCG failure.

• ONCOS-102: Targovax

ONCOS-102 is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor. In February 2021, Targovax announced that ONCOS-102 has received Fast-Track designation in malignant pleural mesothelioma from the US FDA.

Further product details are provided in the report……..

Oncolytic Virus Cancer Therapy: Therapeutic Assessment

This segment of the report provides insights about the different Oncolytic Virus Cancer Therapy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Oncolytic Virus Cancer Therapy

There are approx. 45+ key companies which are developing the Oncolytic Virus Cancer Therapy. The companies which have their Oncolytic Virus Cancer Therapy drug candidates in the most advanced stage, i.e. Phase III include, CG Oncolgy.

• Phases

DelveInsight’s report covers around 85+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Oncolytic Virus Cancer Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Oncolytic Virus Cancer Therapy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Oncolytic Virus Cancer Therapy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Oncolytic Virus Cancer Therapy drugs.

Oncolytic Virus Cancer Therapy Report Insights

• Oncolytic Virus Cancer Therapy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Oncolytic Virus Cancer Therapy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Oncolytic Virus Cancer Therapy drugs?
• How many Oncolytic Virus Cancer Therapy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Oncolytic Virus Cancer Therapy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Oncolytic Virus Cancer Therapy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Oncolytic Virus Cancer Therapy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• CG Oncolgy
• Oncolytics Biotech
• Astellas Pharma
• DNAtrix
• Nouscom
• ImmVira Pharma
• Targovax
• Istari Oncology
• SillaJen Biotherapeutics
• Transgene
• Advantagene
• Wuhan Binhui Biotechnology
• PsiOxus Therapeutics
• VCN Biosciences
• Vyriad
• Oncolys Biopharma
• Replimune
• Oncorus

Key Products

• CG0070
• Pelareorep
• ASP-9801
• DNX 2440
• NOUS PEV
• T3011
• ONCOS-102
• PVS-RIPO
• Pexa-Vec
• Research programme: oncolytic vaccinia virus therapies
• rQNestin 34.5
• oHSV-2
• Enadenotucirev
• NG-348
• NG-350A
• NG-641
• NG-347
• NG-796A
• VCN-01
• Voyager-V1
• TG6002
• BT 001
• Tasadenoturev
• Suratadenoturev
• RP1
• OBP-702
• ONCR-177

Contents

Introduction
Executive Summary
Oncolytic Virus Cancer Therapy: Overview
  Structure
  Mechanism of Action
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
Oncolytic Virus Cancer Therapy – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
  Oncolytic Virus Cancer Therapy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Oncolytic Virus Cancer Therapy Collaboration Deals
  Company-Company Collaborations (Licensing / Partnering) Analysis
  Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  Comparative Analysis
CG0070: CG Oncolgy
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  Comparative Analysis
Pelareorep: Oncolytics Biotech
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
  Comparative Analysis
ASP-9801: Astellas Pharma
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
  Comparative Analysis
Research programme: oncolytic vaccinia virus therapies - AstraZeneca/Transgene
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  Comparative Analysis
Oncolytic Virus Cancer Therapy Key Companies
Oncolytic Virus Cancer Therapy Key Products
Oncolytic Virus Cancer Therapy- Unmet Needs
Oncolytic Virus Cancer Therapy- Market Drivers and Barriers
Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion
Oncolytic Virus Cancer Therapy Analyst Views
Oncolytic Virus Cancer Therapy Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Oncolytic Virus Cancer Therapy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Oncolytic Virus Cancer Therapy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products